

Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

## APR 4 2006

Rossmax Inernational Ltd. c/o Mr. Mark C.H. Lin Regulatory Affairs Manager 12 F., No. 189, Kang chien Road Taipei 114 TAIWAN

Re: K060342

Trade Name: Roossmax Automatic Blood Pressure Monitor, Model MO701k

Regulation Number: 21 CFR 870.1130

Regulation Name: Noninvasive Blood Pressure Measurement System

Regulatory Class: Class II (two)

Product Code: DXN
Dated: February 08, 2006
Received: February 10, 2006

Dear Mr. Lin:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (240) 276-0120. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address <a href="http://www.fda.gov/cdrh/industry/support/index.html">http://www.fda.gov/cdrh/industry/support/index.html</a>.

Sincerely yours,

Bram D. Zuckerman, M.D.

Director

Division of Cardiovascular Devices

Office of Device Evaluation

Center for Devices and Radiological Health

Enclosure

## 2. Statement of Indications for use

## **Indications for Use**

510(k) Number (if known):			
Device Name: Rossmax Automatic Blood Pressure Monitor, Model MO701k			
Indications For Use:			
		·	ı
Prescription Use	AND/OR	Over-The-Counter Use	
(Part 21 CFR 801 Subpart D)	(21 CF	FR 801 Subpart C)	
(PLEASE DO NOT WRIT NEEDED)	E BELOW THIS LIN	NE-CONTINUE ON ANOTHER PAGE	∃ IF
Concurren	ce of CDRH, Office	of Device Evaluation (ODE)	
hilynomena.			
Middle In-Offi			
Division of Cardiovascula 510(10 thumber 400035)	10	Page 1 of1	